JP2007509117A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509117A5
JP2007509117A5 JP2006536168A JP2006536168A JP2007509117A5 JP 2007509117 A5 JP2007509117 A5 JP 2007509117A5 JP 2006536168 A JP2006536168 A JP 2006536168A JP 2006536168 A JP2006536168 A JP 2006536168A JP 2007509117 A5 JP2007509117 A5 JP 2007509117A5
Authority
JP
Japan
Prior art keywords
thiazol
pyrimidin
dimethyl
phenylamino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509117A (ja
JP5164380B2 (ja
Filing date
Publication date
Priority claimed from GB0324599A external-priority patent/GB0324599D0/en
Priority claimed from GB0330013A external-priority patent/GB0330013D0/en
Application filed filed Critical
Priority claimed from PCT/GB2004/004465 external-priority patent/WO2005042525A1/en
Publication of JP2007509117A publication Critical patent/JP2007509117A/ja
Publication of JP2007509117A5 publication Critical patent/JP2007509117A5/ja
Application granted granted Critical
Publication of JP5164380B2 publication Critical patent/JP5164380B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536168A 2003-10-21 2004-10-21 ピリミジン−4−イル−3,4−チオン化合物及び治療におけるその使用 Expired - Fee Related JP5164380B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0324599.0 2003-10-21
GB0324599A GB0324599D0 (en) 2003-10-21 2003-10-21 Compound
GB0330013.4 2003-12-24
GB0330013A GB0330013D0 (en) 2003-12-24 2003-12-24 Compound
PCT/GB2004/004465 WO2005042525A1 (en) 2003-10-21 2004-10-21 Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

Publications (3)

Publication Number Publication Date
JP2007509117A JP2007509117A (ja) 2007-04-12
JP2007509117A5 true JP2007509117A5 (cg-RX-API-DMAC7.html) 2007-12-06
JP5164380B2 JP5164380B2 (ja) 2013-03-21

Family

ID=34553788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536168A Expired - Fee Related JP5164380B2 (ja) 2003-10-21 2004-10-21 ピリミジン−4−イル−3,4−チオン化合物及び治療におけるその使用

Country Status (8)

Country Link
US (1) US7902361B2 (cg-RX-API-DMAC7.html)
EP (1) EP1678171B1 (cg-RX-API-DMAC7.html)
JP (1) JP5164380B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004285745A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415759A (cg-RX-API-DMAC7.html)
CA (1) CA2542880A1 (cg-RX-API-DMAC7.html)
IL (1) IL174994A0 (cg-RX-API-DMAC7.html)
WO (1) WO2005042525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
ES2403558T3 (es) * 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007054725A2 (en) * 2005-11-11 2007-05-18 Cyclacel Limited Combination of a cdk-inhibitor and a hdac-inhibitor
EP2514751A1 (en) * 2005-11-15 2012-10-24 Vertex Pharmaceuticals, Inc. Azaindazoles useful as inhibitor of kinases
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010121675A2 (en) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法
CN113336746A (zh) 2015-08-04 2021-09-03 常州千红生化制药股份有限公司 N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2025151517A1 (en) 2024-01-08 2025-07-17 Wavebreak Therapeutics Limited Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6962792B1 (en) 1996-05-08 2005-11-08 Cyclacel Limited Methods and means for inhibition of Cdk4 activity
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
AU753015B2 (en) 1998-03-04 2002-10-03 Cyclacel Limited Cyclin dependent kinase inhibitor
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2401748A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CZ2004354A3 (cs) * 2001-09-28 2004-06-16 Cyclacel Limited Deriváty N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-fenylaminu
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use

Similar Documents

Publication Publication Date Title
JP2007509117A5 (cg-RX-API-DMAC7.html)
JP2007520540A5 (cg-RX-API-DMAC7.html)
JP2007500178A5 (cg-RX-API-DMAC7.html)
JP2008526824A5 (cg-RX-API-DMAC7.html)
JP2013517283A5 (cg-RX-API-DMAC7.html)
US7915443B2 (en) Sulfoximines as kinase inhibitors
RU2469036C2 (ru) Имидазопиридиновые ингибиторы киназ
JP4988355B2 (ja) 置換ピペラジン
JP2008500320A5 (cg-RX-API-DMAC7.html)
CN1124269C (zh) 取代的嘧啶化合物和其用途
JP2014511869A5 (cg-RX-API-DMAC7.html)
JP2006519258A5 (cg-RX-API-DMAC7.html)
EP1648875A1 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
CN1395566A (zh) 促肾上腺皮质激素释放因子拮抗剂
US20060241297A1 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
JP2013510876A5 (cg-RX-API-DMAC7.html)
CN1592743A (zh) 糖元合成酶激酶3的抑制剂
JP2017526711A5 (cg-RX-API-DMAC7.html)
JP2010215644A5 (cg-RX-API-DMAC7.html)
BG65029B1 (bg) Триазолови съединения и използването им като допамин-d3-лиганди
CN1642931A (zh) 用作新颖的组蛋白去乙酰酶抑制剂的磺酰基衍生物
CN1656073A (zh) 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物
JP2009526072A5 (cg-RX-API-DMAC7.html)
JP2013531055A5 (cg-RX-API-DMAC7.html)
WO2002096867A2 (en) Inhibitors of protein kinase for the treatment of disease